"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors

REFERENCES

• Hu T, Huang L, Cartwright WS (1986) Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 26: 158—63.
   PubMed Web of Science ®Google Scholar
• Hay JW, Ernst RL (1987) The economic costs of Alzheimer’s disease. AmJ Public Health 77: 1169–75.
   PubMed Web of Science ®Google Scholar
• Huang L, Cartwright WS, Hu T (1988) The economic cost of senile dementia in the United States, 1985. Public Health Rep 103: 3–7.
   PubMed Web of Science ®Google Scholar
• Kavanagh S, Schneider J, Knapp M et al (1992) Elderly people with cognitive impairment: costing possible changes in the balance of care. Health Soc Care 1: 69–80.
   Google Scholar
• Gray A, Fenn P (1993) Alzheimer’s disease: the burden of the illness in England. Health Trends 25: 31–7.
   PubMedGoogle Scholar
• Rice DP, Fox PJ, Max W et al (1993) The economic burden of Alzheimer’s disease. Health Affairs 1993: 164—76 (Summer). 4.
   Google Scholar
• Ernst RL, Hay JW (1994) The US economic and social costs of Alzheimer’s disease revisited. AmJ Public Health 84: 1261—4.
   PubMed Web of Science ®Google Scholar
• Ostbye T, Crosse E (1994) Net economic costs of dementia in Canada. Can Med Assoc J 151: 1457–64.
   PubMed Web of Science ®Google Scholar
• Smith K, Shah AQK, Wright K, Lewis G (1995) The prevalence and costs of psychiatric disorders and learning disability. Br J Psychiatry 166: 9–18.
   PubMed Web of Science ®Google Scholar
• Souetre EJ, Qing W, Vigoureux I et al (1995) Economic analysis of Alzheimer’s disease in outpatients: impact of symptom severity. Int Psychogeriatr 7: 115–22.
   PubMedGoogle Scholar
• Souetre E, Thwaites MA, Yeardley HL (1999) Economic impact of Alzheimer’s disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer’s disease. BrJ Psychiatry 174: 51–5.
   PubMed Web of Science ®Google Scholar
• Cavallo MC, Fattore G (1997) The economic and social burden of Alzheimer’s disease on families in the Lombardy region of Italy. Alzheimer’s Dis Rel Disord 11: 184–90.
   PubMed Web of Science ®Google Scholar
• Wimo A, Karlsson G, Sandman PO et al (1997) Cost of illness due to dementia in Sweden. IntJ Geriatr Psychiatry 12: 857–61.
   PubMed Web of Science ®Google Scholar
• Holmes J, Pugner K, Phillips R et al (1998) Managing Alzheimer’s disease: the cost of care per patient. Br J Health Care Manage 4: 332–7.
   Google Scholar
• Leon J, Cheng CK, Neumann PJ (1998) Alzheimer’s disease care: costs and potential savings. Health Affairs 17: 206 — 16.
   Google Scholar
• Andersen CK, Sogaard J, Hansen E et al (1999) The cost of dementia in Denmark: the Odense study. Dement Geriatr Cogn Disord 10: 295–304.
   PubMed Web of Science ®Google Scholar
• O’shea E, O’Reilly S (19??) The economic and social cost of dementia in Ireland, IntJ Geriatr Psychiatry 15: 208–18.
   Google Scholar
• Jorm AF, Korten AE, Henders AS (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76: 465–79.
   PubMed Web of Science ®Google Scholar
• Hofmann A, Rocca WA, Brayne C et al (1991) The prevalence of dementia in Europe: a collaborative study of 1980 — 1990 findings (European collaboration). Int J Epidemiol 20: 736—40.
   Google Scholar
• Shah AK, Ames D (1994) Planning and developing psychogeriatric services. Int Rev Psychiatry 6: 15–27.
   Google Scholar
• Shah AK, Lindesay J. (2001) Cross-cultural issues in the assessment of cognitive impairment. In: O’Brien J, Ames D, Burns A (eds) Dementia. Arnold, London: 217—32.
   Google Scholar
• Rothstein Z, Prohovnik I, Davidson M et al (1996) The economic burden of Alzheimer’s disease in Israel. Israeli J Med Sci 32: 1120— 3.
   Google Scholar
• Welch HG, Walsh JS, Larson EB (1992) The cost of institutional care in Alzheimers disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 40: 221—4.
   PubMed Web of Science ®Google Scholar
• Stommel M, Collins CE, Given BA (1994) The costs of family contributions to the care of persons with dementia. Gerontologist 34: 199—205.
   PubMed Web of Science ®Google Scholar
• Philp I, McKee KJ, Meldrum P et al (1995) Community care for demented and non-demented elderly people: a comparison study of financial burden, service use, and unmet needs in family supporters. BMJ 310: 1503—6.
   Google Scholar
• Knapp MJ, Knopman DS, Solomon PR et al (1994) A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer’s disease. J Am Med Assoc 271: 985—91.
   Google Scholar
• Rogers SL, Doody RS, Mohs RC et al (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a multicentre, randomised, double-blind, placebo-controlled trial. Dementia 7: 293–303.
   PubMedGoogle Scholar
• Donepezil Study Group, Rogers SL, Farlow MR, Doody RS et al (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–45.
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J et al (1999) The effects of donepezil in Alzheimer’s disease: results from a multinational study. Dementia Geriatr Cogn Disord 10: 237–44.
   PubMed Web of Science ®Google Scholar
• ENA 713B303 Study Group, Rosler M, Anand R, Cicin-Sain A et al (1999) Safety and efficacy of rivastigmine in patients with Alzheimer’s disease: results of an international, 26-week multi centre, randomised, placebo-controlled trial. BMJ 318: 633—8.
   Google Scholar
• Wilcock GK, Lilienfelt S, Gaens E, on behalf of the Galanthamine International-1 study group (2000) Efficacy and safety of galanthamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 321: 1445–9
   PubMed Web of Science ®Google Scholar
• Lubeck DP, Mazonson PD, Bowe T (1994) Potential effect of tacrine on expenditures for Alzheimer’s disease. Med Interface 7: 130–8.
   PubMedGoogle Scholar
• Henke CJ, Burchmore MJ (1997) The economic impact of tacrine in the treatment of Alzheimer’s disease. Clin Ther 19: 330—45.
   PubMed Web of Science ®Google Scholar
• Wimo A, Karlsson G, Nordberg A, Winblad B (1997) Treatment of Alzheimer’s disease with tacrine: a cost-analysis model. Alzheimer’s Dis Rel Disord 4: 191–200.
   Google Scholar
• Small GW, Donohue JA, Brooks RL (1998) An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 20: 838–50.
   PubMed Web of Science ®Google Scholar
• Stewart A, Phillips R, Dempsey G (1998) Pharmacotherapy for people with Alzheimer’s disease: a Markov-Cycle evaluation of five years’ therapy using donepezil. IntJ Geriatr Psychiatry 13: 445 — 53.
   Google Scholar
• Jonsson L, Lindgren P, Wimo A et al (1999) The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 21: 1230—40.
   Google Scholar
• Neumann PJ, Hermann RC, Kuntz KM et al (1999) Cost-effectiveness of donepezil in the treatment of mild and moderate Alzheimer’s disease. Neurology 52: 1138—45.
   Google Scholar
• O’Brien BJ, Goeree R, Hux M et al (1999) Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 47: 570–8.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gnanasakthy A, Snyder EH et al (2000) Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigmine. Pharmacoeconomics 17: 351–60.
   PubMed Web of Science ®Google Scholar
• Hux MJ, O’Brien BJ, Iskedjian M et al (1998) Relation between severity of Alzheimer’s disease and costs of caring. Can Med Assoc J 159: 457—65.
   Google Scholar
• Ernst RL, Hay JW, Fenn C et al (1997) Cognitive function and the cost of Alzheimer’s disease. An exploratory study. Arch Neurol 54: 687–93.
   PubMed Web of Science ®Google Scholar
• Wimo A, Witthaus K, Rother M, Winblad B (1998) Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin Ther 20: 552—66.
   PubMed Web of Science ®Google Scholar
• Anonymous (2000) Alzheimer’s patient still left out in the cold. Heath & Ageing October: 12–13.
   Google Scholar
• National Institute for Clinical Excellence (2000) Guidance on use of donepezil, rivastigmine and galanthamine for the treatment of Alzheimer’s disease. Technology Appraisal Guidance, No. 19. National Institute of Clinical Excellence. London.
   Google Scholar